A prospective, open, observational study to confirm the lipid-lowering effect, changes in glucose metabolism, and safety after 6 months of administration of atostazet to hypercholesterolemic patients 65 years of age or older

Inclusion Criteria:

• Males or females aged ≥ 65 years
• Primary Hypercholesterolemia
• moderate risk or higher patient based on Korean Guidelines for the Management of Dyslipidemia (the 4th edition)

Exclusion Criteria:

• Patients with a known hypersensitivity to any of the major or minor components of the study drug
• Patients with active hepatic disease or unexplained persistently elevated serum aminotransferase levels
• Patients with myopathies
• Patients receiving glecaprevir and pibrentasvir

Patients with hypercholesterolemia at moderate risk or higher who are at least 65 years of age and confirmed for treatment